We are live on ! Find out more
AVEO

AVEO Pharmaceuticals

Delisted

AVEO was delisted on the 19th of January, 2023.

81 hedge funds and large institutions have $62M invested in AVEO Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 31 increasing their positions, 25 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 25

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

1% less funds holding

Funds holding: 82 → 81 (-1)

2.24% less ownership

Funds ownership: 60.17% → 57.93% (-2.2%)

11% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 9

34% less capital inflows, than outflows

Capital inflows: $6.28M | Capital outflows: $9.5M

96% less call options, than puts

Call options by funds: $7K | Put options by funds: $188K

Holders
81
Holders Change
-1
Holders Change %
-1.22%
% of All Funds
2.62%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
8
Increased
31
Reduced
25
Closed
9
Calls
$7K
Puts
$188K
Net Calls
-$181K
Net Calls Change
+$269K

AVEO Hedge Fund Activity: Q3 2013 in Review

81 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals (AVEO) for Q3 2013, worth a combined $62M — down 21% from $78.5M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of AVEO and 8 opened new positions — a net loss of 1 holder — while 25 trimmed existing stakes and 31 added.

The largest buyer was TFS Capital, adding an estimated $1.15M. The largest seller was Credit Suisse, cutting an estimated $1.83M.

  • 81 institutional investors held AVEO Pharmaceuticals (AVEO) as of Q3 2013, down from 82 in Q2 2013.
  • Funds reported $62M of AVEO Pharmaceuticals stock for Q3 2013, down 21% quarter-over-quarter.
  • 8 funds opened new AVEO Pharmaceuticals positions in Q3 2013 and 9 closed out, a net change of -1 holder.
  • The largest AVEO Pharmaceuticals buyer in Q3 2013 was TFS Capital, an estimated $1.15M added.
  • The largest AVEO Pharmaceuticals seller in Q3 2013 was Credit Suisse, an estimated $1.83M sold.

Based on aggregated 13F filings for Q3 2013.